A vanadyl complex, bis(6-methylpicolinato)oxovanadium(IV), VO(6MPA), with VO(N 2 O 2 ) coordination mode, was found to exhibit a normoglycemic effect on KKA y mice with hereditary noninsulin-dependent diabetes mellitus with daily oral administration.
Recent intensive research has demonstrated that exogenous vanadyl (oxidation state ϩ4) and vanadate (oxidation state ϩ5) ions both mimic the biological actions of insulin in rat adipocytes in terms of hexose uptake, stimulation of glucose oxidation, and inhibition of lipolysis. [1] [2] [3] [4] However, due to the low insulinomimetic activity of vanadyl (VOSO 4 ) attributed to the solubility and stability of vanadyl ions at neutral pH values, and permeation into cell interior, vanadate ions were exclusively used in such experiments. 6, 7) Vanadate ions administrated orally (in drinking water) to streptozotocin (STZ)-induced hyperglycemic rats, a model of insulindependent diabetes mellitus (IDDM), have been demonstrated to reduce the high levels of circulating glucose levels to normal values. 8, 9) Moreover, it was found that vanadate administration is also effective in experimental models of noninsulin-dependent diabetes mellitus (NIDDM). Oral vanadate therapy in db/db and ob/ob mice induced normoglycemia, 10) while oral administration of insulin failed to do so. 11) Attempts to use vanadyl ions have been made, because vanadate ions have the disadvantage of being 6-to 10-fold more toxic than vanadyl ions. 12) To overcome the solubility of vanadyl ions, autoxidation of vanadyl ions to vanadate, and vanadium toxicity in animals, we have used vanadyl complexes with different coordination modes involving VO(O 4 ), VO(N 2 O 2 ), VO(N 2 S 2 ), and VO(S 4 ). 5, 13) In those systemic investigations, we first examined the complexes for the in vitro insulinomimetic activities such as potentiation of glucose incorporation in rat adipocytes and suppression of free fatty acid (FFA) release from adipocytes treated with epinephrine, 14, 15) and then evaluated the in vivo insulinomimetic action in STZ-induced hyperglycemic rats (STZ rats) with IDDM by intraperitoneal (i.p.) injection or oral administration. [14] [15] [16] [17] [18] Among the complexes, we found that bis(6-methylpicolinato)oxovanadium (IV) (VO(6MPA)) complex is the most effective agent in treating the hyperglycemia of STZ rats in intraperitoneal injection as well as oral administration. 18) On the basis of these observations and results, we further attempted to use VO(6MPA) to treat hyperglycemic animals with NIDDM.
To the authors' knowledge, this paper reports the first example of treating hyperglycemic KKA y mice with NIDDM with the vanadyl complex VO(6MPA) given daily by oral administration.
VO(6MPA) was prepared in aqueous solution, pH 6-7, by mixing 6-methylpicolinic acid (Tokyo Kasei Organic Chemical, Tokyo, Japan) and VOSO 4 (VS) (Nakalai Tesque, Kyoto, Japan) in a molar ratio of 2 : 1, respectively, and washed with water, as reported previously. 18) KKA y mice (Clea Japan, Tokyo, Japan) weighing 30-35 g were divided into 4 groups: 1) control group; 2) intraperitoneal injection VS-treated group; 3) intraperitoneal injection VO(6MPA)-treated group; and 4) oral VO(6MPA)-treated When VO(6MPA) on VS was given to KKA y mice at the dose of V 2.5 mg/kg i.p. for 12 d, blood glucose levels decreased within 4 or 5 d and the levels were maintained during the administration period, while the blood glucose level of the control group was hyperglycemic ( Fig. 1(a) ). The normoglycemic action of VO(6MPA) was stronger than that of VS. The body weight of KKA y mice in each group increased gradually, and the body weight change between groups was not significant. 19) The blood glucose level of KKA y mice treated with oral VO(6MPA) V 5 mg/kg for 2 d and then V 10 mg/kg for 12 d decreased within 4 d and the decrease was maintained during the administration period ( Fig. 1(b) ) as the body weight increased. 20) After cessation of complex adminisration, serum glucose levels increased gradually in mice in both administration groups (Fig. 1) . This differed from the results in STZ rats, in which norglycemia was maintained after cessation of administartion.
18) The fluid intake and food consumption in the VS-and VO(6MPA)-treated intraperitoneal injectin groups as well as in the oral administration group were reduced by about 20% compared with the control group. However, no body weight loss was observed. 19, 20) The serum parameters of KKA y mice treated with VO(6MPA) by oral administration for 14 d (Table 1) suggested that high blood glucose, BUN levels, and hyperinsulinemia of KKA y mice were improved by complex administration. On the basis of these results, the vanadyl complex VO(6MPA) improved NIDDM without body weight loss.
The experimental advantage of using vanadyl compounds to treat diabetes mellitus has been shown in terms of vanadyl incorporation into adipocytes 15) and the presence of vanadyldependent pathways such as membrane protein thyrosine phosphatases (PTPases) and cytosolic protein tyrosine kinases. [1] [2] [3] [21] [22] [23] The PTPases are inhibited in vitro and in vivo by vanadium compounds. [24] [25] [26] Thus vanadium compounds enhance insulin receptor and/or substrate phosphorylation indirectly by inhibiting the dephosphorylation of these proteins, which in turn induce normoglycemia in diabetic animals.
The present study indicates that VO(6MPA) has a normoglycemic effect not only in IDDM model rats 18) but also in NIDDM model mice. Moreover, the high glucose levels as well as high BUN levels observed in NIDDM mice were improved. Therefore VO(6MPA) is expected to be effective in treating milder forms of NIDDM such as that in humans. Furthermore, it has recently been reported that oral vanadate and vanadyl ions both improve the insulin resistance and glucose tolerance that are characteristic of NIDDM patients. 22, 23) Thus the lipophilic vanadyl complex VO(6MPA) 18 ) is a more potent oral therapeutic agent in treating both IDDM and NIDDM than vanadium ions. A more refined investigation involving the mechanism of action of VO(6MPA) is in progress. 
